Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion.

Serrano-Oviedo L, Ortega-Muelas M, García-Cano J, Valero ML, Cimas FJ, Pascual-Serra R, Fernandez-Aroca DM, Roche O, Ruiz-Hidalgo MJ, Belandia B, Giménez-Bachs JM, Salinas AS, Sanchez-Prieto R.

PLoS One. 2018 Jul 26;13(7):e0200878. doi: 10.1371/journal.pone.0200878. eCollection 2018.

2.

Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.

Alcaraz-Sanabria A, Nieto-Jiménez C, Corrales-Sánchez V, Serrano-Oviedo L, Andrés-Pretel F, Montero JC, Burgos M, Llopis J, Galán-Moya EM, Pandiella A, Ocaña A.

Mol Cancer Ther. 2017 Nov;16(11):2552-2562. doi: 10.1158/1535-7163.MCT-17-0223. Epub 2017 Aug 28.

3.

Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.

Salinas-Sánchez AS, Serrano-Oviedo L, Nam-Cha SY, Roche-Losada O, Sánchez-Prieto R, Giménez-Bachs JM.

Clin Genitourin Cancer. 2017 Dec;15(6):e923-e933. doi: 10.1016/j.clgc.2017.05.016. Epub 2017 May 25.

PMID:
28624320
4.

Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors.

Martínez-Canales S, Cifuentes F, López De Rodas Gregorio M, Serrano-Oviedo L, Galán-Moya EM, Amir E, Pandiella A, Győrffy B, Ocaña A.

PLoS One. 2017 May 4;12(5):e0175128. doi: 10.1371/journal.pone.0175128. eCollection 2017.

5.

Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors.

Pérez-Peña J, Alcaraz-Sanabria A, Nieto-Jiménez C, Páez R, Corrales-Sánchez V, Serrano-Oviedo L, Wali VB, Patwardhan GA, Amir E, Győrffy B, Pandiella A, Ocaña A.

Oncotarget. 2017 Mar 28;8(13):21733-21740. doi: 10.18632/oncotarget.15562.

6.

VHL promotes immune response against renal cell carcinoma via NF-κB-dependent regulation of VCAM-1.

Labrousse-Arias D, Martínez-Alonso E, Corral-Escariz M, Bienes-Martínez R, Berridy J, Serrano-Oviedo L, Conde E, García-Bermejo ML, Giménez-Bachs JM, Salinas-Sánchez AS, Sánchez-Prieto R, Yao M, Lasa M, Calzada MJ.

J Cell Biol. 2017 Mar 6;216(3):835-847. doi: 10.1083/jcb.201608024. Epub 2017 Feb 24.

7.

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.

Nieto-Jiménez C, Alcaraz-Sanabria A, Pérez-Peña J, Corrales-Sánchez V, Serrano-Heras G, Galán-Moya EM, Serrano-Oviedo L, Montero JC, Burgos M, Llopis J, Pandiella A, Ocaña A.

Oncotarget. 2017 Mar 21;8(12):19478-19490. doi: 10.18632/oncotarget.14465.

8.

Implication of VHL, ERK5, and HIF-1alpha in clear cell renal cell carcinoma: Molecular basis.

Serrano-Oviedo L, Giménez-Bachs JM, Nam-Cha SY, Cimas FJ, García-Cano J, Sánchez-Prieto R, Salinas-Sánchez AS.

Urol Oncol. 2017 Mar;35(3):114.e15-114.e22. doi: 10.1016/j.urolonc.2016.10.010. Epub 2016 Nov 8.

9.

MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells.

Cimas FJ, Callejas-Valera JL, Pascual-Serra R, García-Cano J, Garcia-Gil E, De la Cruz-Morcillo MA, Ortega-Muelas M, Serrano-Oviedo L, Gutkind JS, Sánchez-Prieto R.

Oncotarget. 2015 Dec 29;6(42):44095-107. doi: 10.18632/oncotarget.6574.

10.

Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance.

García-Cano J, Ambroise G, Pascual-Serra R, Carrión MC, Serrano-Oviedo L, Ortega-Muelas M, Cimas FJ, Sabater S, Ruiz-Hidalgo MJ, Sanchez Perez I, Mas A, Jalón FA, Vazquez A, Sánchez-Prieto R.

Oncotarget. 2015 Jun 20;6(17):15551-65.

11.

E1a promotes c-Myc-dependent replicative stress: implications in glioblastoma radiosensitization.

Valero ML, Cimas FJ, Arias L, Melgar-Rojas P, García E, Callejas-Valera JL, García-Cano J, Serrano-Oviedo L, de la Cruz-Morcillo MÁ, Sánchez-Pérez I, Sánchez-Prieto R.

Cell Cycle. 2014;13(1):52-61. doi: 10.4161/cc.26754. Epub 2013 Oct 11.

12.

ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.

Arias-González L, Moreno-Gimeno I, del Campo AR, Serrano-Oviedo L, Valero ML, Esparís-Ogando A, de la Cruz-Morcillo MÁ, Melgar-Rojas P, García-Cano J, Cimas FJ, Hidalgo MJ, Prado A, Callejas-Valera JL, Nam-Cha SH, Giménez-Bachs JM, Salinas-Sánchez AS, Pandiella A, del Peso L, Sánchez-Prieto R.

Neoplasia. 2013 Jun;15(6):649-59.

13.

Abrogation of the p38 MAPK α signaling pathway does not promote radioresistance but its activity is required for 5-Fluorouracil-associated radiosensitivity.

de la Cruz-Morcillo MA, García-Cano J, Arias-González L, García-Gil E, Artacho-Cordón F, Ríos-Arrabal S, Valero ML, Cimas FJ, Serrano-Oviedo L, Villas MV, Romero-Fernández J, Núñez MI, Sánchez-Prieto R.

Cancer Lett. 2013 Jul 10;335(1):66-74. doi: 10.1016/j.canlet.2013.01.050. Epub 2013 Feb 8.

PMID:
23403078
14.

HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.

Elorza A, Soro-Arnáiz I, Meléndez-Rodríguez F, Rodríguez-Vaello V, Marsboom G, de Cárcer G, Acosta-Iborra B, Albacete-Albacete L, Ordóñez A, Serrano-Oviedo L, Giménez-Bachs JM, Vara-Vega A, Salinas A, Sánchez-Prieto R, Martín del Río R, Sánchez-Madrid F, Malumbres M, Landázuri MO, Aragonés J.

Mol Cell. 2012 Dec 14;48(5):681-91. doi: 10.1016/j.molcel.2012.09.017. Epub 2012 Oct 25.

15.

Carbonic anhydrase IX as a specific biomarker for clear cell renal cell carcinoma: comparative study of Western blot and immunohistochemistry and implications for diagnosis.

Giménez-Bachs JM, Salinas-Sánchez AS, Serrano-Oviedo L, Nam-Cha SH, Rubio-Del Campo A, Sánchez-Prieto R.

Scand J Urol Nephrol. 2012 Oct;46(5):358-64. doi: 10.3109/00365599.2012.685493. Epub 2012 May 10.

PMID:
22571179
16.

[Role of mitogen-activated protein kinase (MAPK) in the sporadic renal cell carcinoma].

Salinas-Sánchez AS, Giménez-Bachs JM, Serrano-Oviedo L, Nam Cha S, Sánchez-Prieto R.

Actas Urol Esp. 2012 Feb;36(2):99-103. doi: 10.1016/j.acuro.2011.07.013. Epub 2011 Sep 28. Review. Spanish.

PMID:
21959062
17.

GSTT1, GSTM1, and CYP1B1 gene polymorphisms and susceptibility to sporadic renal cell cancer.

Salinas-Sánchez AS, Sánchez-Sánchez F, Donate-Moreno MJ, Rubio-del-Campo A, Serrano-Oviedo L, Gimenez-Bachs JM, Martínez-Sanchiz C, Segura-Martín M, Escribano J.

Urol Oncol. 2012 Nov-Dec;30(6):864-70. doi: 10.1016/j.urolonc.2010.10.001. Epub 2011 Apr 1.

PMID:
21458313
18.

Polymorphic deletions of the GSTT1 and GSTM1 genes and susceptibility to bladder cancer.

Salinas-Sánchez AS, Sánchez-Sánchez F, Donate-Moreno MJ, Rubio-del-Campo A, Gimenez-Bachs JM, Lorenzo-Romero JG, Serrano-Oviedo L, Escribano J.

BJU Int. 2011 Jun;107(11):1825-32. doi: 10.1111/j.1464-410X.2010.09683.x. Epub 2010 Oct 13.

Supplemental Content

Loading ...
Support Center